Rebaudioside A glycosyl transferase CvsUGT76 mutant and application thereof
By developing the mutant of glycosyltransferase CvsUGT76 and building an E. coli expression system, the problem of insufficient conversion efficiency in industrial production of high-purity rebaudioside A was solved, and efficient rebaudioside A production and simplified production process were achieved. .
Patent Information
- Application Number
- CN202310555253.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-17
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art cannot meet the industrial production needs of high-purity rebaudioside A, and the conversion efficiency of wild-type glycosyltransferase CvsUGT76 is insufficient.
Develop mutants of glycosyltransferase CvsUGT76, including Y157H/P264H and P264H variants, improve the catalytic efficiency of enzymes by constructing pET32a(+) E. coli expression system, and catalyze stevio glycoside generation in living cells through recombinant strains Glycoside A.
The yield of rebaudioside A was significantly improved, with a conversion rate of 93.5%, simplified the reaction process, and was suitable for industrial production.
Smart Images

Figure BDA0004232764640000061 
Figure BDA0004232764640000071 
Figure BDA0004232764640000081
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of genetic engineering, and in particular to a rebaudioside A glycosyltransferase CvsUGT76 mutant and application thereof. Background Art
[0002] Healthy diet and low-sugar diet are increasingly favored and valued by the market and consumers. Artificial and natural sweeteners, as food additives, are non-toxic and non-carcinogenic. They are ideal natural sweeteners that can safely replace sucrose, and their sweetness is 200 to 300 times that of sucrose. Rebaudioside-A (Reb A) is a diterpene compound found in stevia, a perennial herbaceous plant of the Paraguayan Asteraceae family. Reb A is a representative non-toxic medicinal natural sweetener of steviosides. The sweetness of high-purity Reb A is about 300 to 400 times that of sucrose. Reb A has the functions of regulating blood sugar balance, regulating cardiovascular and reducing hypertension. And there are relevant literature reports proving that it is non-genotoxic and non-carcinogenic. At present, stevioside compounds have been approved as medicinal natural sweeteners by the United States (FDA), the European Food Safety Authority (EFSA), and my country's National Health Commission for use in the production of food and beverages such as candy, cakes, and cocoa products. Compared with steviol glycoside mixtures, high-purity Reb A has no obvious bitter aftertaste and is sweeter than general steviol glycoside extracts. At present, the maximum usage of steviol glycoside sweeteners in various countries is calculated based on steviol as an equivalent. Therefore, high-purity Reb A has stable sweetness and flavor compared with steviol glycoside mixtures during the production process, and has higher added value and market application prospects.
[0003] In order to increase the yield of high-purity rebaudioside A, microbial heterologous synthesis methods have been developed at home and abroad, hoping to obtain high-purity rebaudioside A as a product or as a reaction substrate for the synthesis of downstream rebaudioside D and rebaudioside M. It is currently known that the wild-type glycosyltransferase CvsUGT76 catalyzes the synthesis of rebaudioside A using stevioside and UDP-G (uridine-5'-diphosphoglucose) as substrates, but its conversion efficiency still cannot meet industrial requirements. Therefore, it is necessary to develop new catalytic enzymes or engineered strains to meet the needs of industrial production of rebaudioside A. Summary of the invention
[0004] The technical problem to be solved by the present invention is: how to realize the industrial production of high-purity rebaudioside A.
[0005] In order to solve the above technical problems, in the first aspect, the present invention provides a protein, wherein the protein is a glycosyltransferase CvsUGT76 mutant, and the glycosyltransferase CvsUGT76 mutant is selected from any one of the following proteins:
[0006] A1), a protein named Y157H / P264H, whose amino acid sequence is SEQ ID No. 3;
[0007] A2), a protein named P264H, whose amino acid sequence is SEQ ID No. 2;
[0008] A3), a protein related to glycosyltransferase obtained by substitution and / or deletion and / or addition of amino acid residues in the amino acid sequence shown in A1) and having an identity of more than 80% with the protein shown in A1);
[0009] A4), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A1) or A2).
[0010] Among them, SEQ ID No. 3 and SEQ ID No. 2 consist of 465 amino acid residues respectively.
[0011] The above proteins can be artificially synthesized, or their encoding genes can be synthesized first and then expressed biologically.
[0012] The protein tag refers to a polypeptide or protein that is fused and expressed with the target protein using DNA in vitro recombination technology to facilitate the expression, detection, tracing and / or purification of the target protein. The protein tag can be a Flag protein tag, a His protein tag, an MBP protein tag, an HA protein tag, a myc protein tag, a GST protein tag and / or a SUMO protein tag, etc.
[0013] In a second aspect, the present invention provides a biological material related to the above protein, wherein the biological material is selected from any one of the following:
[0014] B1), a nucleic acid molecule encoding the above protein;
[0015] B2), an expression cassette containing the nucleic acid molecule described in B1);
[0016] B3), a recombinant vector containing the nucleic acid molecule described in B1), or a recombinant vector containing the expression cassette described in B2);
[0017] B4), a recombinant microorganism containing the nucleic acid molecule described in B1), or a recombinant microorganism containing the expression cassette described in B2), or a recombinant microorganism containing the recombinant vector described in B3);
[0018] B5), a transgenic plant cell line containing the nucleic acid molecule described in B1), or a transgenic plant cell line containing the expression cassette described in B2), or a transgenic plant cell line containing the recombinant vector described in B3);
[0019] B6), transgenic plant tissue containing the nucleic acid molecule described in B1), or transgenic plant tissue containing the expression cassette described in B2), or transgenic plant tissue containing the recombinant vector described in B3);
[0020] B7), a transgenic plant organ containing the nucleic acid molecule described in B1), or a transgenic plant organ containing the expression cassette described in B2), or a transgenic plant organ containing the recombinant vector described in B3).
[0021] Furthermore, in the biological material, the nucleic acid molecule in B1) is selected from any one of the following:
[0022] g1), the coding sequence of the coding strand is the DNA molecule shown in SEQ ID No.5 or SEQ ID No.4;
[0023] g2), the nucleotide sequence of the coding strand is the DNA molecule shown in SEQ ID No.5 or SEQ ID No.4;
[0024] g3) A DNA molecule that has 80% or more identity with the nucleotide sequence defined in g1) or g2) and encodes the above-mentioned protein.
[0025] In the present invention, identity refers to the identity of an amino acid sequence or a nucleotide sequence. The identity of an amino acid sequence can be determined using a homology search site on the Internet, such as the BLAST page on the NCBI homepage website. For example, in Advanced BLAST 2.1, by using blastp as a program, setting the Expect value to 10, setting all Filters to OFF, using BLOSUM62 as a Matrix, setting the Gap existence cost, Per residue gap cost and Lambda ratio to 11, 1 and 0.85 (default values) respectively, and searching for the identity of a pair of amino acid sequences for calculation, the identity value (%) can be obtained.
[0026] In the present invention, the above 80% identity may be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity.
[0027] In a third aspect, the present invention provides a method for preparing a recombinant bacterium, the method comprising introducing a nucleic acid molecule encoding the above protein into a recipient bacterium to obtain the recombinant bacterium.
[0028] Furthermore, in the method described above, the recipient bacteria is Escherichia coli.
[0029] Furthermore, in the method, the nucleic acid molecule is selected from any one of the following:
[0030] g1), the coding sequence of the coding strand is the DNA molecule shown in SEQ ID No.5 or SEQ ID No.4;
[0031] g2), the nucleotide sequence of the coding strand is the DNA molecule shown in SEQ ID No.5 or SEQ ID No.4;
[0032] g3) A DNA molecule that has 80% or more identity with the nucleotide sequence defined in g1) or g2) and encodes the above-mentioned protein.
[0033] In a fourth aspect, the present invention provides a recombinant Escherichia coli, wherein the recombinant Escherichia coli expresses the above-mentioned protein.
[0034] Furthermore, the recombinant Escherichia coli is obtained by introducing a nucleic acid molecule encoding the above protein into a recipient Escherichia coli.
[0035] Furthermore, in the recombinant Escherichia coli, the nucleic acid molecule is introduced into the recipient Escherichia coli via a recombinant vector, and the recombinant vector may be a prokaryotic expression vector. In one embodiment of the present invention, the prokaryotic expression vector is pET32a-CvsUGT76(Y157H / P264H) or pET32a-CvsUGT76(P264H).
[0036] In a fifth aspect, the present invention provides a bacterial agent, which includes the above-mentioned recombinant Escherichia coli and / or a culture of the above-mentioned recombinant Escherichia coli.
[0037] In a sixth aspect, the present invention provides the use of the above-mentioned protein or the above-mentioned biological material or the above-mentioned recombinant Escherichia coli in C1) or C2),
[0038] C1) Application in the production of rebaudioside A;
[0039] C1) Application in the preparation of products producing rebaudioside A.
[0040] Furthermore, in the above application, the product may be a reagent or a kit.
[0041] Furthermore, in the above application, the product may be a protein reagent, a recombinant expression cassette, a recombinant vector, a recombinant bacterium or a bacterial agent or a culture of a recombinant bacterium.
[0042] In a seventh aspect, the present invention provides a method for preparing rebaudioside A, comprising using the above-mentioned protein or the above-mentioned biological material or the above-mentioned recombinant Escherichia coli to catalyze stevioside and uridine-5'-diphosphoglucose to obtain rebaudioside A.
[0043] In the present invention, the stevioside used is STV-80 purchased from Zhucheng Haotian Pharmaceutical Co., Ltd., with the item number STV-80M20220109, referred to as STV-80 in the examples. The uridine nucleoside-5'-diphosphate glucose used is uridine diphosphate glucose disodium salt purchased from Shanghai MacLean Biochemical Technology Co., Ltd., with the item number U850073, referred to as UDP-G.
[0044] In an embodiment of the present invention, the reaction system for catalyzing stevioside and uridine-5'-diphosphoglucose to obtain rebaudioside A is as follows: 1) adding 20 mL of the reaction mixture (comprising 5.5 g / L STV-80, 10 g / L UDP-G, and the solvent is water) into a 50 mL conical flask, adding 1 g of the bacterial precipitate of the recombinant strain E. coli BL21 / pET32a-CvsUGT76 (Y157H / P264H) prepared in 1.2, and then adjusting the pH of the mixture to 7.5 with 50 mM sodium phosphate buffer, and reacting at 35°C and 180 rpm. 2) Add 20 mL of the reaction mixture (containing 12 g / L STV-80, 16 g / L UDP-G, and the solvent is water) to a 50 mL Erlenmeyer flask, add 2 g of the recombinant strain E. coli BL21 / pET32a-CvsUGT76 (Y157H / P264H) cell precipitate prepared in 1.2, and then adjust the pH of the mixture to 7.5 with 50 mM sodium phosphate buffer, and react at 35 ° C and 180 rpm.
[0045] The present invention successfully excavated and expressed artichoke-derived glycosyltransferase-like proteins and mutants thereof and performed functional identification, and also successfully constructed the application of Escherichia coli engineering strains to the living cell catalytic reaction of the steviol glycoside compound pauladin RA.
[0046] The glycosyltransferase CvsUGT76 mutant of the present invention is a mutant obtained by mutating the 157th tyrosine and / or the 264th proline of the glycosyltransferase CvsUGT76 derived from Cynara cardunculus (amino acids corresponding to the wild-type sequence of NCBI accession number XM_025137648.1).
[0047] The present invention transforms the glycosyltransferase CvsUGT76 derived from Cynara cardunculus, performs site-directed mutation on the 157th tyrosine and / or the 264th proline of the glycosyltransferase CvsUGT76, and obtains single mutants and double mutants with improved catalytic efficiency.
[0048] The present invention also provides a method for preparing the above-mentioned glycosyltransferase CvsUGT76 mutant, wherein the proline at position 264 in the amino acid sequence of the glycosyltransferase CvsUGT76 shown in SEQ ID N0.1 is mutated to histidine, and / or the tyrosine at position 157 and the proline at position 264 are mutated to histidine.
[0049] In one preferred embodiment of the present invention, the mutant is a mutant in which the proline (Pro) at position 264 of the amino acid sequence of the glycosyltransferase CvsUGT76 shown in SEQ ID NO.1 is mutated to histidine (His) to obtain a mutant with a sequence as shown in SEQ ID NO.2, named CvsUGT76 (P264H).
[0050] In one preferred embodiment of the present invention, the mutant is a mutant in which the tyrosine (Tyr) at position 157 of the amino acid sequence of the glycosyltransferase CvsUGT76 shown in SEQ ID NO.1 is mutated to histidine (His), and the proline (Pro) at position 264 is mutated to histidine (His), to obtain a mutant having a sequence as shown in SEQ ID NO.3, named CvsUGT76 (Y157H / P264H).
[0051] Compared with the prior art, the present invention has the following advantages:
[0052] (1) The present invention constructs a pET32a(+) Escherichia coli expression system for expressing the glycosyltransferase CvsUGT76 and its mutants derived from Cynara cardunculus, thereby solving the problem of overexpression of the UGT family in the prokaryotic expression system.
[0053] (2) The genetically engineered bacteria constructed by the present invention can be stored at -20°C or -80°C. The BL21 (DE3) genetically engineered bacteria are used in the reaction to express the enzyme and complete the living cell reaction catalysis process, which simplifies the reaction process and can be used in actual production.
[0054] (3) The recombinant bacteria expressing the glycosyltransferase mutant constructed by the present invention have an approximately 8.5-fold increase in the production of rebaudioside A in catalyzing stevioside to rebaudioside A compared to the recombinant bacteria expressing the wild-type glycosyltransferase. Under the optimal reaction conditions, the conversion rate of rebaudioside A can reach 93.5%. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] Figure 1 Gel electrophoresis pattern for verification of the expression product of the recombinant strain. DETAILED DESCRIPTION
[0056] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0057] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0058] In the following examples, the contents of rebaudioside A and steviol glycoside were detected by liquid chromatography (HPLC), and HPLC was performed on a Shimadzu LC-2050C 3D CN liquid chromatograph, and rebaudioside A (RebA) and steviol glycoside (STV) were used as standard products for quantitative detection by the standard curve method (external standard method), and the chromatographic analysis conditions were as follows:
[0059] Chromatographic column: AQ NH2 (NAPH);
[0060] Flow rate: 1.5ml / min;
[0061] Wavelength: 210nm;
[0062] Time: 20 minutes;
[0063] Mobile phase: buffer: acetonitrile (20:80);
[0064] Buffer: Dissolve 0.125 g ammonium acetate and 125 μL glacial acetic acid in 1 L water;
[0065] Column temperature: 30℃.
[0066] The stevioside standard product in the following examples is Beijing Solebao Product No. SS9510;
[0067] The rebaudioside A standard in the following examples is Shanghai Aladdin Biochemical Technology Co., Ltd., product number R107557;
[0068] The STV-80 in the following examples was purchased from Zhucheng Haotian Pharmaceutical Co., Ltd., with the item number STV-80M20220109. STV-80 is a stevia direct extraction product of Haotian Pharmaceutical Co., Ltd., and the content of stevia mixture in the product reaches 95%, of which the content of stevia is above 80%;
[0069] UDP-G in the following examples is uridine diphosphate glucose disodium salt, purchased from Shanghai MacLean Biochemical Technology Co., Ltd., product number U850073;
[0070] The host cells E. coli BL21 (DE3) in the following examples are from Shanghai Weidi Biotechnology Co., Ltd., catalog number EC1002.
[0071] The tryptone in the following examples was purchased from OXOID Company with the product number LP0042; the yeast extract was purchased from OXOID Company with the product number LP0021.
[0072] The quantitative tests in the following examples were repeated three times unless otherwise specified, and the results were averaged.
[0073] Example 1. Construction and induced expression of glycosyltransferase CvsUGT76 mutant
[0074] 1.1. Construction of recombinant expression vector
[0075] This example provides a method for constructing an expression vector of a mutant of a glycosyltransferase CvsUGT76 from Cynara cardunculus. The amino acid sequence of the wild-type glycosyltransferase CvsUGT76 is SEQ ID No. 1 (corresponding to NCBI accession number (ACCESSION VERSION) XP_024993416.1 (16-MAY-2018)), and the NCBI accession number of its coding sequence is XM_025137648.1 (16-MAY-2018).
[0076] There are two types of glycosyltransferase CvsUGT76 mutants. One is the glycosyltransferase CvsUGT76 single mutant CvsUGT76 (P264H) whose amino acid sequence is SEQ ID NO.2 and whose coding sequence is a DNA molecule whose nucleotide sequence is SEQ ID NO.4; the other is the glycosyltransferase CvsUGT76 double mutant CvsUGT76 (Y157H and P264H) whose amino acid sequence is SEQ ID NO.3 and whose coding sequence is a DNA molecule whose nucleotide sequence is SEQ ID NO.5.
[0077] Table 1: Glycosyltransferase CvsUGT76 mutant information
[0078]
[0079]
[0080]
[0081] The coding sequence of glycosyltransferase CvsUGT76 from Cynara cardunculus was synthesized by Nanjing Qingke Company (NCBI accession number is XM_025137648.1 (16-MAY-2018)) and constructed into pET32a (+) to obtain a recombinant expression vector pET32a-CvsUGT76, and the fusion protein thioredoxin-glycosyltransferase CvsUGT76 was expressed in the pET32a (+) prokaryotic expression system; wherein the structure of the recombinant expression vector pET32a-CvsUGT76 is as follows: a DNA molecule whose nucleotide sequence is NCBI accession number is XM025137648.1 (16-MAY-2018) replaces a nucleotide fragment between the BamH I and EcoR I restriction recognition sites of the vector pET32a (+), and the rest of the nucleotide sequence of pET32a (+) is kept unchanged to obtain a recombinant expression vector.
[0082] The coding sequence of CvsUGT76 (P264H) (coding sequence SEQ ID NO.4) was synthesized by Nanjing Qingke Company and constructed into pET32a (+) to obtain a recombinant expression vector pET32a-CvsUGT76 (P264H). The structure of the recombinant expression vector pET32a-CvsUGT76 (P264H) is as follows: a nucleotide fragment between the BamH I and EcoR I enzyme recognition sites of the vector pET32a (+) is replaced with a DNA molecule having a nucleotide sequence of SEQ ID No.4, and the remaining nucleotide sequences of pET32a (+) are kept unchanged to obtain a recombinant expression vector.
[0083] The coding sequence of CvsUGT76 (Y157H / P264H) (coding sequence SEQ ID NO.5) was synthesized by Nanjing Qingke Company and constructed into pET32a (+) to obtain a recombinant expression vector pET32a-CvsUGT76 (Y157H / P264H). The structure of the recombinant expression vector pET32a-CvsUGT76 (Y157H / P264H) is as follows: a nucleotide fragment between the BamH I and EcoR I enzyme recognition sites of the vector pET32a (+) is replaced with a DNA molecule having a nucleotide sequence of SEQ ID No.5, and the remaining nucleotide sequences of pET32a (+) are kept unchanged to obtain the recombinant expression vector.
[0084] The recombinant expression vector pET32a-CvsUGT76, the recombinant expression vector pET32a-CvsUGT76 (P264H) or the recombinant expression vector pET32a-CvsUGT76 (Y157H / P264H) were transformed into the host cell E. coli BL21 (DE3). The correctly sequenced recombinant strains E. coli BL21 / pET32a-CvsUGT76, the recombinant strains E. coli BL21 / pET32a-CvsUGT76 (P264H) or the recombinant strains E. coli BL21 / pET32a-CvsUGT76 (Y157H / P264H) were inoculated into 5 mL of ampicillin resistant LB medium, shaken at 180 r / min, and cultured at 37°C for 24 hours. Take the above bacterial solution and inoculate it into 40mL TB medium at a 5% (V / V) inoculation volume and culture at 37°C. When the bacteria grow to OD 600nm When the temperature is 4 to 6, add sterilized glycerol to a final concentration of 20% glycerol in the bacterial solution, and store it in sterile tubes at -80°C. In the following examples, the recombinant strain E. coli BL21 / pET32a-CvsUGT76 (Y157H / P264H) is also called the Y157H / P264H mutant strain.
[0085] The formula of the ampicillin-resistant LB medium is 10 g / L (OXOID) of tryptone, 5 g / L (OXOID) of yeast extract, and 10 g / L of sodium chloride.
[0086] The formula of TB medium is tryptone 12 g / L (OXOID), yeast extract 24 g / L (OXOID), glycerol 5 g / L, potassium hydrogen phosphate trihydrate 16.43 g / L, potassium dihydrogen phosphate 2.31 g / L.
[0087] 1.2. Induced expression of genetically engineered bacteria SDS-PAGE electrophoresis analysis of total protein of genetically engineered bacteria and preparation of crude enzyme solution
[0088] The recombinant strain E. coli BL21 / pET32a-CvsUGT76, recombinant strain E. coli BL21 / pET32a-CvsUGT76(P264H) or recombinant strain E. coli BL21 / pET32a-CvsUGT76(Y157H / P264H) stored in 1.1 were inoculated into a shaking tube containing 5 mL LB liquid culture medium containing ampicillin antibody, and cultured on a shaker at 37°C for 24 h at a speed of 180 rpm. Then, the culture solution was inoculated into a 500 mL shaking flask containing 40 mL TB induction medium at a 5% inoculation amount, and cultured at 200 rpm, 37°C for 2 h. When the OD 600nmWhen the speed reaches about 4-6, the temperature is changed to 200 rpm, and the culture is induced in a shaker at 25°C for 24 hours. The bacterial solution is collected into a centrifuge tube. After centrifugation at 5000 rpm for 5 minutes, the bacterial precipitate is collected and placed at -20°C for use (for experiments in Examples 2-6).
[0089] Take 60 μL of the bacterial solution of the three recombinant strains and add 20 μL of 4* protein loading buffer (Herui Biotechnology) to mark it. After fully mixing, heat it in 100℃ water for 10 minutes. Use the protein gel electrophoresis kit of BIOSS to prepare 1.0mm12% SDS-PAGE gel for electrophoresis verification of protein samples, and Nanjing Qingke Company 2×TSINGKE Master Mix (Blue) as a protein marker (item number TSV-007). After electrophoresis, stain the gel with Coomassie bright stain (microwave oven, medium-high fire for 90s), then pour out the staining solution and add decolorizing solution for decolorization. Decolorize for 2 hours each time until the bands are clear. The decolorizing solution formula is: 450mL methanol, 100mL glacial acetic acid, and 450ml water.
[0090] The experimental results are shown in Figure 1 . Figure 1 This is the gel electrophoresis pattern for verification of the expression product of the recombinant strain, where M is a marker, and the band sizes from bottom to top are 180, 130, 95, 70, 55, 43, 33, 20, 17, and 10 kDa. Lane 1 is the expression product of the recombinant strain E. coli BL21 / pET32a-CvsUGT76, lane 2 is the expression product of the recombinant strain E. coli BL21 / pET32a-CvsUGT76(P264H), and lane 3 is the expression product of the recombinant strain E. coli BL21 / pET32a-CvsUGT76(Y157H / P264H). The sizes of the three expressed proteins are all between 60 and 70 kDa. Figure 1 The results showed that the recombinant strain E. coli BL21 / pET32a-CvsUGT76, the recombinant strain E. coli BL21 / pET32a-CvsUGT76(P264H) or the recombinant strain E. coliBL21 / pET32a-CvsUGT76(Y157H / P264H) had obvious expression at the target position and the target expression product could be obtained.
[0091] The glycosyltransferase expressed by the recombinant strain E. coli BL21 / pET32a-CvsUGT76 was named TRX-CvsUGT76; the glycosyltransferase expressed by the recombinant strain E. coli BL21 / pET32a-CvsUGT76(P264H) was named TRX-CvsUGT76(P264H); the glycosyltransferase expressed by the recombinant strain E. coli BL21 / pET32a-CvsUGT76(Y157H, P264H) was named TRX-CvsUGT76(Y157H / P264H).
[0092] Example 2, enzyme activity determination
[0093] In a 50 mL conical flask, add 20 mL of the reaction mixture (containing 5 g / L STV-80, 10 g / L UDP-G, the rest is water, and the pH of the mixture is adjusted to 7.0 with 50 mM sodium phosphate buffer), and then add the recombinant strain E. coli BL21 / pET32a-CvsUGT76, recombinant strain E. coli BL21 / pET32a-CvsUGT76 (P264H) or recombinant strain E. coli prepared in 1.2, respectively. 1 g of BL21 / pET32a-CvsUGT76 (Y157H / P264H) bacterial precipitate (indicated by wild type, P264H and Y157H / P264H in Table 2) was reacted at 35°C and 180 rpm for 0 to 24 h. Samples were taken at 0, 2, 6 and 24 hours of culture and heated at 95°C for 5 min to inactivate the enzyme. The supernatant was collected by centrifugation and the rebaudioside A concentration was detected by high performance liquid chromatography (HPLC). Three replicates were set for each recombinant strain and the results were averaged. The results are shown in Table 2. The results in Table 2 show that the activity of the glycosyltransferase TRX-CvsUGT76(P264H) expressed by the recombinant strain E. coli BL21 / pET32a-CvsUGT76(P264H) or the glycosyltransferase TRX-CvsUGT76(Y157H / P264H) expressed by the recombinant strain E. coli BL21 / pET32a-CvsUGT76(P264H) is higher than that of the wild-type glycosyltransferase expressed by the recombinant strain E. coli BL21 / pET32a-CvsUGT76.
[0094] The composition of 50mM sodium phosphate buffer is pH=7.0, 0.1M, and the formula for 1L is to dissolve NaH2PO4·2H2O 15.6g / L and Na2HPO4·12H2O 35.816g / L in water to make the volume to 1L, and then add ddH2O to dilute to 50mM.
[0095] Table 2 Enzyme activity determination results
[0096]
[0097] Example 3: Determination of the optimal pH for enzyme activity reaction
[0098] 20 mL of reaction mixture (containing 5.5 g / L STV-80, 10 g / L UDP-G, solvent is water) was added to a 50 mL conical flask, and 1 g of the recombinant strain E. coli BL21 / pET32a-CvsUGT76 (Y157H / P264H) cell precipitate prepared in 1.2 was added, and then the pH of the mixture was adjusted to 5.5, 6.0, 6.5, 7.0, and 7.5 with 50 mM sodium phosphate buffer, respectively, and the reaction was carried out at 35°C and 180 rpm. After 24 hours of reaction, the sample was heated at 95°C for 5 minutes to inactivate the enzyme, and the supernatant was centrifuged and the concentration of rebaudioside A was detected by high performance liquid chromatography (HPLC). Three replicates were set for each recombinant strain, and the results were averaged. The results are shown in Table 3. The results in Table 3 show that when pH = 5.5, the enzyme activity of TRX-CvsUGT76 (Y157H / P264H) was significantly inhibited. Then, the net increment of rebaudioside A was close at pH=6.0, pH=6.5, and pH=7.0. At pH=7.5, the net increment of rebaudioside A was significantly increased compared with the previous one, and the subsequent reaction was carried out at pH=7.5.
[0099] Table 3 Results of determination of optimal pH for enzyme activity reaction
[0100] pH 0hRebaudioside A (g / L) 24h Rebaudioside A (g / L) Net increase of rebaudioside A (g / L) 5.5 0.677 1.707 1.030 6.0 0.798 4.560 3.762 6.5 0.813 4.770 3.957 7.0 0.818 4.689 3.871 7.5 0.974 5.345 4.371
[0101] Example 4: Determination of the optimal temperature for enzyme activity reaction
[0102] In a 50 mL conical flask, 20 mL of the reaction mixture (containing 5.5 g / L STV-80, 10 g / L UDP-G, and the solvent was water) was added, and 1 g of the bacterial precipitate of the recombinant strain E. coli BL21 / pET32a-CvsUGT76 (Y157H / P264H) prepared in 1.2 was added, and then the pH of the mixture was adjusted to 7.5 with 50 mM sodium phosphate buffer, and the reaction was carried out at 25°C, 35°C, 45°C, and 55°C at 180 rpm. After reacting for 24 hours, the sample was heated at 95°C for 5 minutes to inactivate the enzyme, and the supernatant was taken by centrifugation. The concentration of rebaudioside A was detected by high performance liquid chromatography (HPLC). Three replicates were set for each recombinant strain, and the results were averaged. The results are shown in Table 4. The results in Table 4 show that 35°C is the appropriate temperature for the enzyme activity reaction of TRX-CvsUGT76 (Y157H / P264H), and the net increase of rebaudioside A is significantly higher than that under other temperature conditions. At the same time, the reaction proves that the temperature above 35°C has a certain inhibitory effect on the enzyme activity. Subsequent experiments are carried out at 35°C.
[0103] Table 4 Results of determination of optimal temperature for enzyme activity reaction
[0104] Temperature(℃) 0hRebaudioside A (g / L) 24h Rebaudioside A (g / L) Net increase of rebaudioside A (g / L) 25 0.606 4.646 4.04 35 0.617 5.145 4.528 45 0.648 2.48 1.832 55 0.584 1.17 0.586
[0105] Example 5: Determination of the reaction rate of enzyme activity of the Y157H / P264H mutant
[0106] In a 50 mL conical flask, 20 mL of the reaction mixture (containing 5.5 g / L STV-80, 10 g / L UDP-G, and the solvent was water) was added, and 1 g of the bacterial precipitate of the recombinant strain E. coli BL21 / pET32a-CvsUGT76 (Y157H / P264H) prepared in 1.2 was added, and then the pH of the mixture was adjusted to 7.5 with 50 mM sodium phosphate buffer, and the reaction was carried out at 35 ° C and 180 rpm. After the reaction for 0.5 h, the sample was heated at 95 ° C for 5 min to inactivate the enzyme, and the supernatant was taken by centrifugation. The concentration of rebaudioside A was detected by high performance liquid chromatography (HPLC). Three replicates were set for each recombinant strain, and the results were averaged. The results of the optimal bacterial dosage for determining the enzyme activity reaction are shown in Table 5.
[0107] Table 5 Results of enzyme activity reaction rate determination of Y157H / P264H mutant
[0108] Bacterial dosage g 0hRebaudioside A (g / L) 0.5h Rebaudioside A (g / L) Net increase of rebaudioside A (g / L) 0.5 0.683 0.996 0.313 1 0.664 1.349 0.685 1.5 0.648 1.419 0.771 2 0.757 1.823 0.866
[0109] Example 6: Determination of the conversion ratio of rebaudioside by the Y157H / P264H mutant
[0110] In a 50 mL conical flask, 20 mL of the reaction mixture (containing 12 g / L STV-80, 16 g / L UDP-G, and the solvent was water) was added, and 2 g of the bacterial precipitate of the recombinant strain E. coli BL21 / pET32a-CvsUGT76 (Y157H / P264H) prepared in 1.2 was added, and then the pH of the mixture was adjusted to 7.5 with 50 mM sodium phosphate buffer, and the reaction was carried out at 35 ° C and 180 rpm. The sample was heated at 95 ° C for 5 min to inactivate the enzyme, and the supernatant was taken by centrifugation. The concentration of rebaudioside A was detected by high performance liquid chromatography (HPLC), and the optimal reaction time of the enzyme activity reaction was determined. The reaction was continued until rebaudioside A no longer changed. The detailed measurement results are shown in Table 6.
[0111] Table 6 Results of the determination of the rebaudioside conversion ratio of the Y157H / P264H mutant
[0112] Reaction time Stevia(g / L) Rebaudioside A(g / L) Changes in rebaudioside A 0h 10.097 0.761 0.5h 9.099 2.815 1.054 1h 7.947 3.588 0.773 1.5h 6.922 4.742 1.154 2h 5.408 5.885 1.143 3h 4.413 6.707 0.822 4h 2.852 9.154 2.447 5h 1.678 10.229 1.075 7h 0.705 11.3 1.071 8h 0.706 11.301 0.001
[0113] The crude enzyme solution obtained after induction expression of the recombinant strain E.coli BL21 / pET32a-CvsUGT76 (Y157H / P264H) was used for the reaction. In a 50mL triangular flask, 20mL of the reaction mixture contained 12g / L STV-80, 16g / L UDP-G, 50mM sodium phosphate buffer at pH7.5, and the amount of bacteria was 2g. The reaction was carried out at 35°C and 180rpm. The sample was heated at 95°C for 5min to inactivate the enzyme, and the supernatant was taken by centrifugation. The highest yield of rebaudioside A in the reaction solution was 11.301g / L. Compared with the STV-80 content measured at 0h, its conversion rate reached 93.5%.
[0114] The two groups are calculated at 0h and 8h respectively, and the conversion rate is calculated as follows:
[0115] Conversion rate = (reacted rebaudioside - initial rebaudioside) / [(initial stevioside - reacted stevioside) / 805 (stevioside molecular weight) * 967 (rebaudioside molecular weight)] * 100%.
[0116] The present invention is not limited to the above specific embodiments, which are only for the purpose of describing the use of the present invention in detail, and the production methods and technical details with equivalent functions also belong to the content of the present invention. In fact, those skilled in the art can find different adjustment schemes according to their respective needs based on the above description, and these adjustments should be within the scope of the claims attached hereto.
[0117] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.
Claims
1. Protein, characterized in that: The protein is a glycosyltransferase CvsUGT76 mutant, and the glycosyltransferase CvsUGT76 mutant is selected from any one of the following proteins: A1), a protein named Y157H / P264H, whose amino acid sequence is SEQ ID No. 3; A2), a protein named P264H, whose amino acid sequence is SEQ ID No. 2; A3), a protein related to glycosyltransferase obtained by substitution and / or deletion and / or addition of amino acid residues in the amino acid sequence shown in A1) and having an identity of more than 80% with the protein shown in A1); A4), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A1) or A2).
2. A biological material related to the protein of claim 1, characterized in that: The biological material is selected from any one of the following: B1), a nucleic acid molecule encoding the protein according to claim 1; B2), an expression cassette containing the nucleic acid molecule described in B1); B3), a recombinant vector containing the nucleic acid molecule described in B1), or a recombinant vector containing the expression cassette described in B2); B4), a recombinant microorganism containing the nucleic acid molecule described in B1), or a recombinant microorganism containing the expression cassette described in B2), or a recombinant microorganism containing the recombinant vector described in B3); B5), a transgenic plant cell line containing the nucleic acid molecule described in B1), or a transgenic plant cell line containing the expression cassette described in B2), or a transgenic plant cell line containing the recombinant vector described in B3); B6), transgenic plant tissue containing the nucleic acid molecule described in B1), or transgenic plant tissue containing the expression cassette described in B2), or transgenic plant tissue containing the recombinant vector described in B3); B7), a transgenic plant organ containing the nucleic acid molecule described in B1), or a transgenic plant organ containing the expression cassette described in B2), or a transgenic plant organ containing the recombinant vector described in B3).
3. The biomaterial according to claim 2, characterized in that: B1) The nucleic acid molecule is selected from any one of the following: g1), the coding sequence of the coding strand is the DNA molecule shown in SEQ ID No.5 or SEQ ID No.4; g2), the nucleotide sequence of the coding strand is the DNA molecule shown in SEQ ID No.5 or SEQ ID No.4; g3) A DNA molecule that has 80% or more identity with the nucleotide sequence defined in g1) or g2) and encodes the protein described in claim 1.
4. A method for preparing a recombinant bacterium, characterized in that: The method comprises introducing a nucleic acid molecule encoding the protein of claim 1 into a recipient bacterium to obtain the recombinant bacterium.
5. The method according to claim 4, characterized in that: The recipient bacteria is Escherichia coli.
6. The method according to claim 4 or 5, characterized in that: The nucleic acid molecule is selected from any one of the following: g1), the coding sequence of the coding strand is the DNA molecule shown in SEQ ID No.5 or SEQ ID No.4; g2), the nucleotide sequence of the coding strand is the DNA molecule shown in SEQ ID No.5 or SEQ ID No.4; g3) A DNA molecule that has 80% or more identity with the nucleotide sequence defined in g1) or g2) and encodes the protein described in claim 1.
7. A recombinant Escherichia coli, characterized in that: The recombinant Escherichia coli expresses the protein described in claim 1.
8. A bacterial agent, characterized in that: The bacterial agent includes the recombinant Escherichia coli described in claim 7 or / and a culture of the recombinant Escherichia coli described in claim 7.
9. Use of the protein according to claim 1, the biological material according to claim 2 or 3, or the recombinant Escherichia coli according to claim 7 or 8 in C1) or C2), C1) Application in the production of rebaudioside A; C1) Application in the preparation of products producing rebaudioside A.
10. A method for preparing rebaudioside A, the method comprising using the protein described in claim 1 or the biological material described in claim 2 or 3 or the recombinant Escherichia coli described in claim 7 or 8 to catalyze stevioside and uridine-5'-diphosphoglucose to obtain rebaudioside A.
Citation Information
Cited By
UDP-glucosyltransferase mutant and method for preparing rebaudioside D by using UDP-glucosyltransferase mutant
CN120813686A
